Xeris Biopharma Holdings (XERS) Return on Equity (2021 - 2026)

Xeris Biopharma Holdings has reported Return on Equity for 6 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, down 3.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.43% in Q4 2023, with the low at 0.07% in Q3 2023.
• Historically, Return on Equity has averaged 0.03% across 5 years, with a median of 0.01% in 2026.
• Annual changes were most pronounced in 2023 — Return on Equity jumped 45 bps — and 2024, when it sank 41 bps.
• Xeris Biopharma Holdings' Return on Equity stood at 0.02% in 2022, then jumped by 2360 bps to 0.43% in 2023, then slumped by 96 bps to 0.02% in 2024, then tumbled by 95 bps to 0.0% in 2025, then jumped by 941 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.